David G Le Couteur’s research while affiliated with Concord Hospital and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (558)


Prevalence of heart failure pharmacotherapy utilisation, frailty and adverse drug events among hospitalised adults older than 75 years: a multicentre cross-sectional study
  • Article

December 2024

·

14 Reads

Internal Medicine Journal

Mai H Duong

·

Danijela Gnjidic

·

·

[...]

·

Background Optimal heart failure (HF) pharmacotherapy (guideline‐directed medical therapy and diuretics) in older people with frailty is uncertain due to limited evidence. Aims To evaluate utilisation of HF pharmacotherapy and prevalence of polypharmacy, adverse drug events (ADEs), falls, delirium, renal impairment and duration of hospitalisation in older inpatients, according to frailty. Methods A retrospective cross‐sectional study of the TO HOME cohort of 2000 inpatients ≥75 years admitted for ≥48 h to rehabilitation, geriatric or general medicine from 1 July 2016 to 30 June 2017 across six hospitals in Sydney, Australia. Data were collected from electronic medical records. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification identified HF diagnosis, ADEs and frailty using hospital frailty risk score. Outcomes included utilisation of HF pharmacotherapy; polypharmacy; ADEs, falls, delirium, renal and impairment; and duration of hospitalisation. Results Among 439 (22.0% of TO HOME cohort) patients with undifferentiated HF, 284 (69.5%) had intermediate or high risk of frailty, and 412 (94%) took ≥1 HF pharmacotherapy, with 357 (81.3%) patients on loop diuretics. Patients with high frailty risk frequently continued beta‐blockers (70%) and discontinued renin‐angiotensin system inhibitors (57%). Most patients experienced polypharmacy ( n = 426, 97.0%). Renal impairment prevalence was 67%–76% across frailty groups. Increasing frailty risk (low, intermediate and high) was associated with increasing prevalence of ADEs (31%, 56% and 84%), falls (12%, 25% and 46%) and delirium (8%, 27% and 49%) and longer hospitalisation. Conclusions Frailty, HF‐pharmacotherapy changes in hospital and ADEs were common among older inpatients with HF. The association of adverse outcomes according to frailty needs further investigation. Poor documentation of HF phenotype may be a barrier to medication optimisation in older inpatients.


The Geometric Framework for Nutrition and Its Application to Rodent Models

November 2024

·

3 Reads

Annual Review of Animal Biosciences

Rodents have been the primary model for mammalian nutritional physiology for decades. Despite an extensive body of literature, controversies remain around the effects of specific nutrients and total energy intake on several aspects of nutritional biology, even in this well-studied model. One approach that is helping to bring clarity to the field is the geometric framework for nutrition (GFN). The GFN is a multidimensional paradigm that can be used to conceptualize nutrition and nutritional effects, design experiments, and interpret results. To date, more than 30 publications have applied the GFN to data from rodent models of nutrition. Here we review the major conclusions from these studies. We pay particular attention to the effects of macronutrients on satiety, glucose metabolism, lifespan and the biology of aging, reproductive function, immune function, and the microbiome. We finish by highlighting several knowledge gaps that became evident upon reviewing this literature.


Hepatic proteome signatures of chronic monotherapy and polypharmacy. (a) Healthy male C57BL/6J mice were aged until they reached 12 months old before randomization into drug treatment allocation to receive either control, monotherapy, or polypharmacy. The monotherapy feed contains only one of the five medications in the polypharmacy regimen at the same therapeutic dose. The mice underwent drug treatment until the age of 21 months when they were re‐randomized to either continue treatment or to deprescribe all medications. Deprescribing occurred over the course of 6 weeks. Overall, this amounts to 13 different treatment groups: Control, six chronic (continuous) drug treatment groups (polypharmacy and five monotherapies), and six corresponding deprescribing groups. This study applied (functional) behavioral data at the age of 24 months. At the age of 26 months, the mice were terminated and livers were collected. Sample sizes for hepatic proteomics analysis: Control, n = 8; oxybutynin, n = 6; oxycodone, n = 5; citalopram, n = 6, simvastatin, n = 6; metoprolol, n = 4; polypharmacy, n = 8; oxybutynin deprescribed, n = 6; oxycodone deprescribed, n = 5; citalopram deprescribed, n = 6, simvastatin deprescribed, n = 6; metoprolol deprescribed, n = 5; polypharmacy deprescribed, n = 8. (b) Heatmap after semi‐supervised hierarchical clustering of all differentially expressed proteins across the chronic monotherapies and polypharmacy against control animals (false discovery rate [FDR]‐adjusted p < 0.10; fold change [FC] > ±1.50). Hierarchical clustering was conducted with Euclidean distance and complete linkage. Column clustering was performed with predetermined treatment allocation whereas row clustering was unsupervised. Heatmap is color‐coded with row z‐score scaling with red indicating higher abundance and blue indicating lower. Proteins that were significantly different comparing chronic drug versus control pairwise comparison are annotated as bars on the right of the heatmap within their corresponding drug column. (c) Dot plot showing over‐representation analysis of selected gene ontology (GO) pathways enriched in chronic drug treatment compared with control, with size of dots proportional to protein ratio and colors representing FDR‐adjusted p‐value. (d) The number of shared (overlapping) and unique differentially expressed proteins across treatment groups are recorded within an UpSet plot. The total number of differentially expressed proteins in each chronic drug treatment was noted as the horizontal bar plot on the left.
Comparing hepatic signatures of chronic monotherapy and polypharmacy. (a) Drug synergism score across the 260 differentially expressed proteins in the polypharmacy signature. Horizontal dotted line at score = 1.00 indicates threshold that determines synergistic (>1.00) or sub‐additive effects (≤1.00). (b) Box plots of Hmgcr, Ugt1a9, Ugdh, and Ighm. Synergistic score was annotated. Differential expression result comparing chronic pharmacotherapy against control; * False discovery rate (FDR)‐adjusted p < 0.10, **p < 0.05, ***p < 0.01, ****p < 0.001. (c) Alluvial plot that depicts the single‐most dominant drug driver of each protein within the polypharmacy signature, creating five drug clusters with varying contributions. Protein counts and proportion (%) are shown. (d) Dot plot showing selected gene ontology (GO) pathways enriched in the five “dominant drug” clusters within the polypharmacy signature, with size of dots proportional to protein counts and colors representing FDR‐adjusted p‐value.
Probing for pharmacologically relevant proteins. (a) Protein–drug interaction network derived from Search Tool for Interacting Chemicals (STITCH) database with protein nodes (circle), drug nodes (rhombus), and their interactions color‐coded accordingly. Protein–protein interaction edges are in gray. Only proteins that were quantified in our proteomics dataset (n = 123) are depicted in the network (full network in Figure S4a). (b) Heatmap summarizing differential expression analysis results of pharmacologically relevant proteins. Only proteins with significant change comparing chronic drug treatment against control were depicted; * False discovery rate (FDR)‐adjusted p < 0.10, **p < 0.05, ***p < 0.01, ****p < 0.001. The known drug interactor with the proteins was annotated by the colored bar on the right‐hand side column of the heatmap. Serum levels of (c) drug metabolites and (d) drug parents from 24‐month‐old mice comparing polypharmacy (n = 16) against the corresponding monotherapies (oxybutynin [n = 18], oxycodone [n = 19], citalopram [n = 11], simvastatin [n = 16], and metoprolol [n = 14]). Six drug metabolites were quantified (one for each drug and two for metoprolol), while only four parent drug molecules were successfully quantified. Data are represented as mean ± SEM. Two‐tailed Student's t test was conducted and significance was recorded: *p < 0.05, **p < 0.01, ***p < 0.001.
Different molecular effects of deprescribing medications. (a) Grouped bar plot illustrates the proportion of differentially expressed proteins (determined from the comparison of chronic drug versus control) that were reversible or irreversible upon deprescribing (based on chronic drug versus deprescribing; see Figure S7 for different deprescribing outcomes and Table S2 for differential expression analysis results). Raw protein count recorded on the y‐axis and percentage (%) was noted in the figure. (b) Heatmap summary of the different deprescribing outcomes on drug‐metabolizing enzymes and transporters (see full data on Figure S8 and Table S2). Chronic drug effects (against control) were color‐coded based on log2(fold change [FC]) (red indicating upregulation and blue indicating downregulation). Only significant results were colored accordingly (false discovery rate [FDR]‐adjusted p < 0.10 and FC > ±1.50) and non‐significant comparisons were colored gray. Shapes indicate deprescribing outcomes: (i) reversible (circle), (ii) irreversible (cross), and novel deprescribing effect (triangle). Drug‐metabolizing enzyme and transporter classes were annotated. (c) Dot plot summarizing pathway analysis result on selected gene ontology (GO) terms for reversible, irreversible, and novel deprescribing effects in each chronic drug treatment. Size of dots represents the protein count of a given term and colors represent FDR‐adjusted p‐value.
Hepatic histology of chronic monotherapy, polypharmacy, and deprescribing, alongside transcriptome signature of chronic polypharmacy. (a) Stacked bar plots of different histological features across different treatment groups (n = 6–15/group). Colors indicate severity of a given histological feature, except for tumors which are binary (0: absent and 1: present). alpha smooth muscle actin (α‐SMA) stains for activated stellate cells. Sample sizes for hepatic histological analysis: Control, n = 14–15; oxybutynin, n = 11–12; oxycodone, n = 9–11; citalopram, n = 6, simvastatin, n = 6; metoprolol, n = 8–9; polypharmacy, n = 8–9; oxybutynin deprescribed, n = 9; oxycodone deprescribed, n = 8–10; citalopram deprescribed, n = 10, simvastatin deprescribed, n = 8–9; metoprolol deprescribed, n = 9–10; polypharmacy deprescribed, n = 9–10. (b) Estimates of ordinal logistic regression with Bayes framework, except for tumors, for which logistic regression was applied. Control was used as a reference group. Error bars depict 99% credible interval (CI) and statistical significance is considered when 99% CI does not cross 0 and critical value of z > 2.575. Estimates (x‐axis) are displayed in log‐scale. Significant estimates are marked with color‐filled mean points. A negative significant estimate (<0) suggests that a given treatment has a lower histological score compared with control whereas a positive significant estimate (>0) suggest a higher one. (c) Volcano plot depicting polypharmacy versus control in the transcriptome level (n = 6/group). Vertical lines represent ±1.50 fold change (FC) and the horizontal lines depict raw p < 0.05 and false discovery rate (FDR)‐adjusted p < 0.05. (d) Scatterplot of RNA (y‐axis) and protein (x‐axis) log2(FC) derived from the differential expression analysis (polypharmacy versus control) on 5967 protein–transcript pairs. Pearson's correlation coefficients (R) and p‐values are shown. Dotted lines represent ±1.50 FC. (e) Pathway‐level comparison as 2D annotation enrichment plot of log2(FC) enrichment score at the RNA (y‐axis) and protein (x‐axis) levels. Higher positive log2(FC) score represents greater degree of upregulation, and vice versa for downregulation. A score at or near 0 indicates that a given pathway experienced no change. The 2D plot can be divided into four quadrants to indicate the concordance and discordance of regulation directionality between the proteome and the transcriptome. Gene ontology (GO) terms and Kyoto encyclopedia of genes and genome (KEGG) pathways are color‐coded, and selected enrichment are highlighted. All enrichment data point depicted are significant enrichment (FDR <0.01) with dot sizes representing p‐values.

+1

Chronic polypharmacy, monotherapy, and deprescribing: Understanding complex effects on the hepatic proteome of aging mice
  • Article
  • Full-text available

October 2024

·

78 Reads

Polypharmacy (use of ≥5 concurrent medications) is highly prevalent among older adults to manage chronic diseases and is linked to adverse geriatric outcomes, including physical and cognitive functional impairments, falls, frailty, hospitalization, and mortality. Deprescribing (withdrawal) is a potential strategy to manage polypharmacy. The broad molecular changes by which polypharmacy causes harm and deprescribing may be beneficial are unknown and unfeasible to study rigorously in tissue from geriatric patients. Therefore, in a randomized controlled trial, we administered therapeutic doses of commonly used chronic medications (oxycodone, oxybutynin, citalopram, simvastatin, or metoprolol) as monotherapy or concurrently (polypharmacy) from middle‐age (12 months) to old‐age (26 months) to male C57BL/6J (B6) mice and deprescribed (gradually withdrew) treatments in a subset from age 21 months. We compared drug‐related hepatic effects by applying proteomics along with transcriptomics and histology. We found that monotherapy effects on hepatic proteomics were limited but significant changes were seen with polypharmacy (93% unique to polypharmacy). Polypharmacy altered the hepatic expression of proteins involved in immunity, and in drug, cholesterol, and amino acid metabolism, accompanied by higher serum drug levels than monotherapies. Deprescribing not only reversed some effects but also caused irreversible and novel changes in the hepatic proteome. Furthermore, our study identified several hepatic protein co‐expressed modules that are associated with clinically relevant adverse geriatric outcomes, such as mobility, frailty, and activities of daily living. This study highlights the complex molecular changes following aging, chronic polypharmacy, and deprescribing. Further exploration of these mechanistic pathways may inform management of polypharmacy and deprescribing in older adults.

Download

Fig. 1 | Representative scanning electron microscopy (SEM) images showing fenestration changes after treatment with LDL in different concentrations and degree of oxidation. The images demonstrate the loss of sieve plates following treatment on male rat liver sinusoidal endothelial cells (LSECs). A Control LSEC SEM image showing typical fenestrations grouped in sieve plates. B, C 3/24 h copper sulfate-induced oxidized LDL (oxLDL 3/24 , 80 μg/mL, 30 min) treated LSEC SEM images with increasing oxidation levels showing a pronounced loss of sieve plates and uniform fenestration distribution. D, E: oxLDL 3/24 (80 μg/mL, 30 min) treated LSEC SEM images with increasing oxidation levels showing the appearance of large trans-cytoplasmic gaps. Scale bar: 2 μm. Table shows analyzed fenestrations and gap data within cells with sieve plate loss (SP loss) or large gaps (Gap). The data were analyzed based on the representative figures above.
Fig. 3 | Fluorescence microscopy of rat LSECs from male rats, comparing between cells cultured in RPMI only (control) and those treated with 80 µg/mL oxLDL 24 . Upper row shows the merged channels stained for the cell nucleus (DAPI -blue), α-tubulin fibers (antibody against α-tubulin coupled
Fig. 4 | Endocytosis of FSA bound to 125 Iodine in male and female rat LSECs preincubated with oxLDL in vitro. Normalized to control (RPMI). Different doses (10/40/80 μg/mL) of oxLDLs treated LSEC cultures were incubated for 2 h at 37 °C with trace amounts of 125 I-FSA to assay for the main LSEC endocytosis receptors (stabilin1/2). Endocytosis was measured as described in Materials and Methods. Black bars represent cell-associated FSA (%CA), whereas the grey-striped bars represent degraded FSA (%DL). Total endocytosed radioactivity represents the sum of cell-associated and degraded ligand radioactivity, average of n = 3 animals per sex calculated.
Fig. 5 | Differential KLF2 gene expression in response to LDL and oxLDL treatments. Fold change in KLF2 expression (log2) relative to untreated control across different conditions is shown. LDL treatments (10, 40, 80 µg/mL) and oxLDL treatments (3 h and 24 h oxidation at 10, 40 and 80 µg/mL) were analysed in three
Impact of oxidized low-density lipoprotein on rat liver sinusoidal endothelial cell morphology and function

October 2024

·

34 Reads

Atherogenesis is associated with elevated plasma levels of oxidized low-density lipoproteins (oxLDL). In vivo, oxLDL causes liver endothelial swelling, and disrupts liver sinusoidal endothelial cell (LSECs) fenestrations. We mapped the nanoscale kinetics of these changes in vitro in isolated rat LSECs challenged with oxLDL and monitored viability with endocytosis and cytotoxicity assays. OxLDL disrupted LSEC ultrastructure – increasing oxLDL concentrations and oxidation levels caused sieve plate loss, fenestration fusion, and gap formation. Importantly, these effects were not uniform across all LSECs. LSECs retained the ability to endocytose ligands irrespective of the presence of oxLDL. However, increasing oxidation levels and concentrations of oxLDL inhibited LSEC mediated degradation of endocytosed ligands. Viability was unaffected by any oxLDL challenge. In conclusion, oxLDL disrupts LSEC ultrastructural morphology in vitro but LSECs remain viable and mostly maintain the scavenging function during oxLDL challenge.


Consort flow diagram for recruitment, randomisation, data collection and analysis.
Dietary compliance and macronutrient intake; Plots showing the difference between consumed and available macronutrients (a–c). These plots show that macronutrients consumption was not different from what was offered in the diet. Plots (d–f) show that consumed protein (as percentage of energy) was similar across all dietary groups, whereas carbohydrate and fat differed by group which is in line with the dietary intervention. Statistics derived from ANOVA fitting diet as a four‐level category.
Changes in dietary intake resulted from dietary intervention and effect of intervention on self‐reported appetite measures; changes in carbohydrate (x‐axis) and fat (y‐axis) intake (g) according to diet (a); bivariate mean change in carbohydrate (x‐axis; ± SD as horizontal lines) and fat (y‐axis; ± SD as vertical lines) intake (g) according to diet (b); proportional change in fat, fibre and carbohydrate (%E); %E carbohydrate implicit; %E protein not included as it was the same for all groups (14%E) (c). Absolute carbohydrate intake was reduced in all diets, absolute fat intake was increased in all diets but OHF. Those randomised to the OHF diet had a significantly higher desire for savoury food scores (d). Hunger and desire for savoury foods (e) followed a very similar pattern throughout the day. BL, baseline assessment; FN, final assessment; OHC, omnivorous high carbohydrate; OHF, omnivorous high fat; VHC, semi‐vegetarian high carbohydrate; VHF, semi‐vegetarian high fat.
Predictors of change in FGF‐21 levels; Cumming plots showing changes FGF‐21 (a) by diet. Scatter plots showing the relationship between changes in FGF‐21 levels and change in protein intake (b), correlation between baseline and final FGF‐21 (c) and relationship between logged final FGF‐21 and final protein intake (d). Error bars are 95% confidence intervals found by bootstrapping. BL, baseline assessment; FN, final assessment; OHC, omnivorous high carbohydrate; OHF, omnivorous high fat; VHC, semi‐vegetarian high carbohydrate; VHF, semi‐vegetarian high fat.
Predictors of change in body composition and selected markers of cardiometabolic health; Cumming plots showing body weight (a), fat mass (b), fat free mass (c), diastolic blood pressure [DP] (d), cholesterol (e) and glucose levels (f) by diet. Error bars are 95% confidence intervals found by bootstrapping. BL, baseline assessment; FN, final assessment; OHC, omnivorous high carbohydrate; OHF, omnivorous high fat; VHC, semi‐vegetarian high carbohydrate; VHF, semi‐vegetarian high fat.
Rapid benefits in older age from transition to whole food diet regardless of protein source or fat to carbohydrate ratio: Arandomised control trial

July 2024

·

113 Reads

Plant‐based diets reduces the risk of chronic conditions. The interaction between protein source and other macronutrients—fat (F) and carbohydrate (C)—has yet to be investigated. The aim was to assess the main and interactive effects of protein‐source (plant vs. animal) and F:C (high or low) and the transition from an Australian diet to a whole food diet on various health markers in older individuals. This single‐blinded, parallel, randomised experimental trial used a 2 × 2 factorial design to compare pro‐vegetarian (70:30 plant to animal) versus omnivorous (50:50 plant to animal) diets at 14% protein and varying fat‐to‐carbohydrate ratios (high fat ~40% vs. low fat ~30%) over 4 weeks. Study foods were provided, alcohol consumption was discouraged, and dietary intake was determined through food records. Analysis included both RCT and observational data. Changes in appetite, palatability of diets, and dietary intake were assessed. Body composition, muscle strength, function, gut microbiome, and cardiometabolic health parameters were measured. Data from 113 (of the 128 randomised) individuals aged 65–75 years were analysed. Pro‐vegetarian diets reduced diastolic blood pressure, total cholesterol and glucose levels. Moreover, the overall sample exhibited increased short‐chain fatty acids and FGF21 levels, as well as improvements in body composition, function, and cardio‐metabolic parameters irrespective of dietary treatment. Transitioning to a diet rich in fruit, vegetables, fibre, and moderate protein was associated with improved health markers in older age, with added benefits from pro‐vegetarian diets. Further research on long‐term effects is needed.


Figure 2. Uptake of radiolabelled molecules by (A) FCS-starved and non-starved primary mouse hepatocytes and (B) primary mouse liver sinusoidal endothelial cells. Results are normalized per 100,000 cells for hepatocytes and per 250,000 cells for LSEC. Cells from a total of three mice shown.
Figure 3. Western blot of C57BL/6J mouse livers stained with anti-Aβ 1−16 antibody. Lanes 1 contain 5 µL of SeeBlue Plus2 Pre-Stained Protein Standard. Lanes 2 and 3 are total protein ex from mouse livers (n = 2) after IVC injection of 45 µg of Aβ40. Lanes 4 and 5 (n = 2) are total p extracts from non-injected mouse livers. Lanes 6 to 8 are Aβ40 standards. Arrow indicates m meric Aβ40 band. Bottom inset is α-tubulin stain of lanes 2 to 5 showing total protein loading
The effect of age on the recovery of Aβ40, Evans Blue and sucrose. Data presented as mean ± SD.
Understanding the Liver’s Role in the Clearance of Aβ40

May 2024

·

22 Reads

Livers

The clearance of peripheral beta amyloid (Aβ) is a potential target for the treatment of Alzheimer’s disease (AD). The liver has been implicated in the elimination of Aβ from the peripheral circulation. Here, the single-pass uptake of Aβ40 in perfused livers from young and old rats (6 to 10 rats per group) was investigated with the multiple indicator dilution technique. Aβ40 had volumes of distribution between those of the vascular marker Evans Blue and the extracellular marker sucrose. The hepatic extraction of Aβ40 was negligible, explained in part by the small permeability surface area products consistent with a high endothelial barrier to liver uptake. There were no substantial effects of age on any of these results. In vitro experiments with isolated hepatocytes and liver sinusoidal endothelial cells showed only very small amounts of Aβ uptake consistent with low intrinsic clearance. These results indicate that the hepatic clearance of Aβ is capacity-limited, explained by the low-permeability surface area products and hepatocyte uptake. However, this does not preclude an effect of aging in longer-term in vivo studies where age-related changes in liver blood flow and protein binding influence liver clearance.


Title: Cross-sectional associations between nutrient intake and tooth decay in older Australian men: The Concord Health and Ageing in Men Project

May 2024

·

14 Reads

Caries Research

Poor nutrition is a risk factor for dental decay in younger people. However, except for sugar it is unclear if this is true in older age groups. The aim of this study was to analyze the possible associations between overall dietary intake of nutrients and diet quality and presence of dental decay in community dwelling older men. A cross-sectional analysis of a longitudinal study with a standardized validated diet history assessment and comprehensive oral health examination in 520 community dwelling men (mean age: 84 years) participating in the Concord Health and Ageing in Men Project. Nutrient Reference Values (NRVs) were used to determine if individual micronutrients and macronutrients were meeting recommendations. Acceptable Macronutrient Distribution Ranges (AMDR) were attained for fat and carbohydrate intakes and were incorporated into a dichotomous variable to determine if the participants were consuming a high fat and low carbohydrate diet. Diagnosis of coronal caries was based on visual criteria and inspection and was completed on each of the five coronal surfaces. Root surface caries was textual changes across four root surfaces. This diagnosis was used to categorize participants by presence and severity of coronal and root caries. Adjusted logistic regression showed not meeting the recommended intakes for thiamin (odds ratio (OR): 2.32 95% confidence interval (CI) 1.15 - 4.67), and zinc (OR: 3.33, 95% CI 1.71 – 6.48) were associated with presence of severe root decay. Adjusted analysis also showed that participants who were outside the recommended AMDR for fat (OR: 0.61, 95% CI 0.38 – 0.98), and those who consumed a high fat and low carbohydrate diet (OR: 0.56, 95% CI 0.35 – 0.91) were less likely to have coronal tooth decay. Our study shows associations between micronutrients and macronutrients and coronal and root surface decay. Although this study cannot prescribe causality or be generalized to all older adults, diet has a possible association with dental decay in older men.


Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee

March 2024

·

43 Reads

·

4 Citations

Journal of the American Geriatrics Society

The International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee aims to improve the use of drugs in older adults and develop new therapeutic approaches for the syndromes and diseases of old age through advocacy, education, and research. In the present paper, we propose strategies relevant to drug development and evaluation, spanning preclinical and the full range of clinical studies. Drugs for older adults need to consider not only age, but also other characteristics common in geriatric patients, such as multimorbidity, polyphar-macy, falls, cognitive impairment, and frailty. The IUPHAR Geriatric Committee's position statement on 'Measurement of Frailty in Drug Development and Evaluation' is included, highlighting 12 key principles that cover the spectrum of translational research. We propose that where older adults are likely to be major users of a drug, that frailty is measured at baseline and as an outcome. Preclinical models that replicate the age, frailty, duration of exposure, comorbidities, and co-medications of the proposed patients may improve translation. We highlight the potential application of recent technologies, such as physiologically based pharmacokinetic-pharmacodynamic modeling informed by frailty biology, and Artificial Intelligence, to inform personalized medicine for older patients. Considerations for the rapidly aging populations in low- and middle-income countries related to health-care and clinical trials are outlined. Involving older adults, their caregivers and health-care providers in all phases of research should improve drug development, evaluation, and outcomes for older adults internationally.



Figure 1. Flow chart of CHAMP study assessment waves. Data for the present study were collected at Wave 3 and Wave 4. The physical function outcome variables measured were grip strength and walking speed, and the physical disability outcome variables measured were ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living).
The association of dietary antioxidants and the inflammatory potential of the diet with poor physical function and disability in older Australian men: The Concord Health and Ageing in Men Project

January 2024

·

44 Reads

·

1 Citation

The British journal of nutrition

Our objective was to evaluate the association of antioxidant intake and the inflammatory potential of the diet with functional decline in older men. A diet history questionnaire was used to collect dietary intake data from men aged ≥ 75 years ( n = 794) participating in the Concord Health and Aging in Men Project cohort study. Intake of vitamins A, C, E, and zinc were compared to the Australian Nutrient Reference Values to determine adequacy. The Energy-adjusted Dietary Inflammatory Index (E-DII TM ) was used to assess the inflammatory potential of the diet. Physical performance data was collected via handgrip strength and walking speed tests, and Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) questionnaires, at baseline and 3-year follow-up ( n = 616). Logistic regression analysis was used to identify associations between diet and incident poor physical function and disability. Both poor antioxidant intake and high E-DII scores at baseline were significantly associated with poor grip strength and ADL disability at 3-year follow-up. No significant associations with walking speed or IADL disability were observed. Individual micronutrient analysis revealed a significant association between the lowest two quartiles of vitamin C intake and poor grip strength. The lowest quartiles of intake for vitamins A, C, E, and zinc were significantly associated with incident ADL disability. The study observed that poor antioxidant and anti-inflammatory food intake were associated with odds of developing disability and declining muscle strength in older men. Further interventional research is necessary to clarify the causality of these associations.


Citations (71)


... There are, however, international efforts to increase the representativeness of participants in clinical trials to match the intended real-world users of the medications across a range of characteristics including age, multimorbidity, polypharmacy and frailty [21]. A central concept in ageing research is frailty because it strongly relates to advanced age and adverse health among older adults [22]. ...

Reference:

Pre-clinical Models for Geriatric Pharmacotherapy
Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee

Journal of the American Geriatrics Society

... Results from our study are consistent with the findings of two recent meta-analyses of both cohort and observational studies, where a reduction in risk of both prevalent [66] and incident [67] frailty in older adults (greater than 60 years of age) was found to be associated with increasing adherence to the MedDiet. In the Australian setting, the relationship between dietary patterns and frailty was also explored in a prospective cohort study, where it was found that a diet rich in vegetables, legumes, and seafood (core MedDiet components) was associated with reduced prevalence of frailty in older community-dwelling Australian men [68]. These data are in keeping with our findings, where higher adherence to the MedDiet using the ASPREE-MDS was associated with a reduced risk of both pre-frailty (aRR 0.93 [95% CI 0.91-0.95]) ...

Cross-sectional and longitudinal associations between empirically derived dietary patterns and frailty among older men: The Concord Health and Ageing in Men Project
  • Citing Article
  • January 2024

The Journal of Nutrition Health and Aging

... Lifestyle factors are modifiable factors, even in old age, and changes in lifestyle factors are likely to have differential impacts and improvements on health [10,11]. Moreover, the impacts could differ by gender [18,21]. In Taiwan, the number of elderly people with functional disabilities continues to increase [6,7]. ...

The association of dietary antioxidants and the inflammatory potential of the diet with poor physical function and disability in older Australian men: The Concord Health and Ageing in Men Project

The British journal of nutrition

... The oral bioavailability and targeting of these drugs toward hepatocytes are significantly improved by the incorporation of QDs into their formulation. Although metformin and nicotinamide mononucleotide are already capable of being absorbed orally, their effectiveness is greatly enhanced when combined with QDs, which lead to a rise of 100-10,000 times in potency and overcoming the diminished efficacy associated with aging [118] (Table 1). ...

Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia

Nature Nanotechnology

... Indeed, Solon-Biet et al. found that sweet preference for sugar water depends on the carbohydrate balance. Mice on a high-carbohydrate diet drank less sucrose, while those on a low-carbohydrate diet consumed more sucrose [42]. The studies of nutritional geometry also indicate that the protein content of the diet drives energy intake from a solid diet [43]. ...

Toward reconciling the roles of FGF21 in protein appetite, sweet preference, and energy expenditure
  • Citing Article
  • December 2023

Cell Reports

... The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE ™ ) trial has demonstrated that a 25% reduction in caloric intake over 2 years in young and middle-aged individuals without obesity led to sustained weight loss, reduced visceral fat, with modest muscle loss, and improvements in cardiometabolic health and blood pressure, all without compromising quality of life (Shen et al., 2021;Kraus et al., 2019). Through linear mixed-effect models, researchers observed DRassociated shifts in gene expression related to proteostasis, circadian rhythm, DNA repair, mitochondrial function, apoptosis, and inflammation (Das et al., 2023). Collectively, these findings indicate that DR may help reduce age-related risk factors also in humans. ...

Diet composition, adherence to calorie restriction, and cardiometabolic disease risk modification
  • Citing Article
  • October 2023

... Furthermore, several compounds were shown to be effective in the refenestration of pseudocapillarized LSECs, e.g. sildenafil, nicotinamide mononucleotide or serotonin [2,16,23,24]. However, refenestration strategies using cytochalasin B were reported to not be completely successful in LSEC defenestration associated with chronic heart failure [10]. ...

Effect of caffeine and other xanthines on liver sinusoidal endothelial cell ultrastructure

... The prevalence of sarcopenic obesity varies depending on the diagnostic criteria used for defining this condition. One example is an Australian study in men, which found prevalence rates of 12.6% for sarcopenia but only 0.3% for sarcopenic obesity using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria (15). Another study found a rate of 9.6% for sarcopenic obesity using the ESPEN/ EASO criteria, relating this diagnosis to parameters of low strength and activities of daily living (16). ...

Sarcopenia prevalence and functional outcomes in older men with obesity: Comparing the use of the EWGSOP2 sarcopenia versus ESPEN-EASO sarcopenic obesity consensus definitions
  • Citing Article
  • July 2023

Clinical Nutrition

... Free iron reacts with oxygen to generate reactive oxygen species, which can damage lipids and lead to lipid peroxidation, ultimately resulting in ferroptosis and even cell death [26,27]. Importantly, studies have confirmed that among elderly men aged 75 and above, a higher intake of heme iron is associated with an increased risk of congestive cardiac failure [28]. The clinical symptoms of iron deficiency, including fatigue, are often confused with those of the primary disease because they are not specific. ...

Haem Iron Intake Is Associated with Increased Major Adverse Cardiovascular Events, All-Cause Mortality, Congestive Cardiac Failure, and Coronary Revascularisation in Older Men: The Concord Health and Ageing in Men Project

The Journal of Nutrition Health and Aging

... The use of multiple medications is common in older adults, increasing the risk of adverse drug reactions (ADRs) in this population [1,2]. This risk is heightened by exposure to potentially inappropriate medicines (PIMs), together with the physiological changes associated with aging, which lead to altered pharmacodynamic and pharmacokinetic activity of medications [3]. ...

Towards Optimizing Hospitalized Older adults' MEdications (TO HOME): Multi‐centre study of medication use and outcomes in routine care